The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many
relevant gene–drug associations have been discovered, but PGx-guided treatment needs to …

Background: In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-
cause mortality and cardiovascular hospitalizations and slows decline in quality of life …

Importance Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently
approved for lowering low-density lipoprotein cholesterol in heterozygous familial …

Background Inclisiran is a novel, cholesterol-lowering therapy, with a long duration of effect,
administered every 6 months (subcutaneously by a healthcare professional). In the ORION …

Purpose To examine the evidence on the cost-effectiveness of implementing
pharmacogenomics (PGx) in cardiovascular disease (CVD) care. Methods We conducted a …

Despite dramatic drops in DNA sequencing costs, concerns are great that the integration of
genomic sequencing into clinical settings will drastically increase health care expenditures …

Objective Due to extended application of pharmacogenetic and pharmacogenomic
screening (PGx) tests it is important to assess whether they provide good value for money …

Purpose Pharmacogenomics (PGx) studies how inherited genetic variations in individuals
affect drug absorption, distribution, and metabolism. PGx panel testing can potentially help …

Background: Platelet inhibition after percutaneous coronary intervention (PCI) reduces the
risk of myocardial infarction (MI) but increases the risk of bleeding. MIs and bleeds during …